
Yannis K. Valtis, MD, discusses real-world outcomes for obecabtagene autoleucel and brexucabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Your AI-Trained Oncology Knowledge Connection!


Yannis K. Valtis, MD, is an oncologist at Memorial Sloan Kettering Cancer Center focusing on leukemia and cellular therapy.

Yannis K. Valtis, MD, discusses real-world outcomes for obecabtagene autoleucel and brexucabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.